Nutriband Inc. Added to Four Russell Indexes in 2025 Reconstitution

Nutriband Inc. (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. This inclusion signifies a notable achievement for the company, reflecting its growing market recognition and the momentum behind its AVERSA pipeline. CEO Gareth Sheridan emphasized the importance of this milestone, particularly pointing to the potential of AVERSA Fentanyl, which is projected to generate peak annual U.S. sales between $80 million and $200 million. The Russell indexes, maintained by FTSE Russell, serve as a benchmark for approximately $10.6 trillion in assets, making this inclusion a significant indicator of Nutriband's market position and future growth potential.

The AVERSA technology, developed by Nutriband, is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, marking a critical advancement in transdermal pharmaceutical products. The company's focus on developing abuse-deterrent technologies positions it as a key player in addressing the ongoing opioid crisis and other drug abuse challenges. For more details on Nutriband's achievements and its AVERSA technology, visit https://ibn.fm/wa35e.